Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations
Open Access
- 1 January 2007
- journal article
- Published by Springer Nature in Osteopathic Medicine and Primary Care
- Vol. 1 (1) , 14
Abstract
Anemia is an underrecognized but characteristic feature of chronic kidney disease (CKD), associated with significant cardiovascular morbidity, hospitalization, and mortality. Since their inception nearly two decades ago, erythropoiesis-stimulating agents (ESAs) have revolutionized the care of patients with renal anemia, and their use has been associated with improved quality of life and reduced hospitalizations, inpatient costs, and mortality. Hemoglobin targets ≥13 g/dL have been linked with adverse events in recent randomized trials, raising concerns over the proper hemoglobin range for ESA treatment. This review appraises observational and randomized studies of the outcomes of erythropoietic treatment and offers recommendations for managing renal anemia in the primary care setting.Keywords
This publication has 71 references indexed in Scilit:
- Anemia as a Predictor of Cardiovascular Events in Patients with Elevated Serum CreatinineJournal of the American Society of Nephrology, 2006
- Anemia in chronic kidney disease: causes, diagnosis, treatment.Cleveland Clinic Journal of Medicine, 2006
- The prevalence of anemia in patients with chronic kidney diseaseCurrent Medical Research and Opinion, 2004
- Health care utilization among patients with chronic kidney diseaseKidney International, 2002
- Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey.2002
- Use of Erythropoietin Before the Initiation of Dialysis and Its Impact on MortalityAmerican Journal of Kidney Diseases, 2001
- Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobinAmerican Journal of Kidney Diseases, 1999
- Does early anemia correction prevent complications of chronic renal failure?1999
- Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for interventionAmerican Journal of Kidney Diseases, 1996
- Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patientsAmerican Journal of Kidney Diseases, 1995